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Abstract 27 
Aims 28 
Immunotherapy with anti-HER2 antibody has shown promising results in patients with 29 
HER2-positive breast cancer. We have recently reported characterization of a mouse 30 
monoclonal antibody (mAb) against HER2, which binds to an epitope different from that 31 
recognized by Trastuzumab and specifically inhibits proliferation of tumor cells 32 
overexpressing HER2. In the present study we report chimerization of this antibody.  33 
Materials and Methods 34 
The immunoglobulin variable region heavy (VH) and light (VL) chain genes of 1T0 35 
hybridoma cells were amplified and ligated to human gamma-1 and kappa constant 36 
region genes using Splice Overlap Extension (SOE) PCR. The chimeric antibody was 37 
subsequently expressed and characterized by ELISA, Western blot and flow cytometry.  38 
Results 39 
The purified chimeric antibody specifically binds to recombinant HER2 and HER2 40 
overexpressing tumor cells and inhibited proliferation of these cells. The binding affinity 41 
of the chimeric mAb was comparable to the parental mouse mAb.  42 
Conclusion 43 
This chimeric anti-HER2 mAb is potentially a valuable tool for targeted immunotherapy. 44 
 45 
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Introduction 48 
The human proto-oncogen HER2, also known as ErbB2 is located on chromosome 17 49 
and encodes a 185 kDa transmembrane glycoprotein that belongs to the epidermal 50 
growth factor receptor (EGFR) family of receptor tyrosine kinases [1]. HER2 acts as the 51 
preferred heterodimerization partner for other members of HER receptors (HER1/ 52 
EGFR, HER3 and HER4) and triggers several downstream signaling cascades such as 53 
MAPK and PI3K/AKT pathways [2]. HER2 gene overexpression is found in a number of 54 
human malignancies including breast cancer, pancreatic adenocarcinoma, ovarian and 55 
colorectal cancers [3, 4]. Overexpression of HER2 correlates with tumor metastasis and 56 
poor prognosis. Approximately 30% of women with breast cancer have HER2 protein 57 
overexpression, which is associated with poor prognosis [5]. The oncogenic potential 58 
and accessibility of HER2 have made it a suitable target for cancer immunotherapy by 59 
monoclonal antibodies (mAbs). Trastuzumab (Herceptin, Genentech Inc., San 60 
Francisco Calif, USA) represents the first humanized mAb which was approved by the 61 
United States Food and Drug Administration (FDA) in 1998, for therapeutic use in 62 
patients with HER2-overexpressing breast cancer [6]. However, many patients do not 63 
respond and progress within 1 year of initiating Trastuzumab therapy, which could be 64 
due to the inefficiency of Trastuzumab to inhibit HER2 binding to other members of the 65 
HER family [7].  66 
Combination of two mAbs recognizing two distinct epitopes on HER2 is an effective 67 
alternative strategy to overcome this resistance [8]. Pertuzumab is another humanized 68 
mAb that binds to an epitope on domain II of the extracellular region of HER2, different 69 
from the binding site of Trastuzumab on domain IV. Consequently, it potently blocks 70 
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ligand-activated signaling transduced from HER-2/HER-1 and HER-2/HER3 71 
heterodimers. Antitumoral activity of Pertuzumab has been shown both in vitro and in vivo 72 
models [9]. Combination of Pertuzumab and Trastuzumab has recently demonstrated 73 
improved survival in patients with breast cancer [10]. Based on these findings, FDA has 74 
recently approved Pertuzumab in combination with Trastuzumab for patients with 75 
HER2-positive metastatic breast cancer [11]. Development of new HER2 specific mAbs 76 
may improve the therapeutic efficacy of the current anti-cancer treatment protocols. In 77 
the present study, we present data on chimerization of a new mouse mAb against 78 
HER2 [12], which binds to an epitope of HER2 different from that of Trastuzumab.  79 
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Materials and Methods 80 
 81 
Cell lines 82 
The 1T0 monoclonal antibody producing hybridoma was prepared as described previously [12]. It 83 
was grown in RPMI 1640 Medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal 84 
bovine serum (Gibco), 100 µg/mL streptomycin, and 100U/mL penicillin (Gibco) at 37ºC in a 85 
humidified atmosphere of 5% CO2. HER2-overexpressing human breast cancer cell line BT-474 86 
and CHO-K1 were purchased from National Cell Bank of Iran (NCBI, Tehran, Iran) and cultured 87 
under similar conditions, with the exception of BT-474 culture medium which was also 88 
supplemented with 10 µg/mL insulin (Exir Co., Boroojerd, Iran). 89 
 90 
Amplification, cloning and sequencing of antibody variable region genes 91 
Variable regions of the heavy chain (VH) and light chain (VL) of 1T0 antibody were amplified by 92 
RT (reverse transcriptase)-PCR using RNA isolated from the hybridoma. In brief, total RNA was 93 
isolated with RNA Bee-RNA Isolation Reagent (AMS Biotechnology, UK) from 1×107 murine 94 
hybridoma cells that secrete 1T0 antibody, and the corresponding cDNA was synthesized with 95 
avian myeloblastosis virus (AMV) reverse transcriptase using oligo dT as primer (Fermentas, 96 
Thermo Fisher Scientific Inc, USA). The VH gene was amplified using the degenerate primers 97 
mUIgVH-S and mUIgGHC-AS and the VL gene was amplified using the degenerate primers 98 
mUIgVkL-S and mIgkC-AS (Table 1). PCR reactions were performed in 25 μl volume, 99 
containing 1 μl of cDNA, 6 and 1μM of forward and reverse primers, respectively, 2 mM MgSo4 100 
concentration, 1u/μl Pfu DNA polymerase (Fermentas) and 10X reaction buffer. After 3 min 101 
denaturation at 94ºC, the PCR reaction was followed by 45 cycles of 1 min at 92ºC, 1 min at 102 
52ºC, 1 min at 72ºC and a final 72ºC for 10 min. To confirm the identity of PCR products, the VH 103 
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and VL genes of 1T0 were cloned into pGEM-T easy vector system (Promega, Madison, WI, 104 
USA) and sequenced.  105 
 106 
Isolation of human IgG1 and IgCκ constant region genes 107 
Similarlr to VH and VL, Cκ of human kappa chain and CH of human IgG1 were amplified by RT–108 
PCR, using the RNA isolated from human peripheral blood mononuclear cell (PBMC). The Cκ was 109 
amplified using the primers Cκ-S and XhoICK-AS and the CH was amplified using the primers CH-S 110 
and BamhICH-AS (Table 1). PCR reactions were performed in 25 μl volume, containing 1 μl of 111 
cDNA, 1μM primers, 2 mM MgSo4, 1u/μl Pfu DNA polymerase (Fermentas) and 10X reaction buffer. 112 
After 3 min denaturation at 94ºC, the PCR reaction was continued by 30 cycles of 1 min at 92ºC, 1 113 
min at 58ºC, 1.5 min at 72ºC and a final 10 min 72ºC. To confirm the validity of PCR products, the 114 
CH and CL genes were cloned into pGEM-T vector system (Promega) and sequenced. 115 
 116 
Construction of the mouse-human chimeric antibody expression vector 117 
using Splice Overlap Extension (SOE) PCR 118 
Splice overlap extension (SOE) PCR allows the fusion of two sequences of DNA without the 119 
use of restriction enzymes [13]. PCR products of VH and VL genes were modified to contain 120 
restriction sites, Kozak sequences and a leader sequence taken from the original cDNA of 121 
1T0 hybridoma in the forward primers and 15bp complementary region of CH and CL in the 122 
reverse primers (Table 1), respectively. The VH, CH and VL, CL were amplified, extracted 123 
from gel and fused during PCR1, as the overlapping sequences. They were subsequently 124 
hybridized and extended to produce full-length chimeric VH-CH and VL-CL sequences. The 125 
VH-CH and VL-CL obtained from PCR1 were then amplified by external primers (VH-SalI-T-126 
S, BamhICH-AS for VH-CH and Vκ-kpn-T-S, Cκ-S for VL-CL) in a second round of PCR 127 
(PCR2). The PCR product of VH-CH was inserted into pBudCE4.1 (Invitrogen, Grand 128 
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Island, NY, USA) at SalI/BamHI restriction sites to generate pBud-VH-CH, which contains 129 
the heavy chain sequence of mouse-human chimeric antibody. After sequencing and 130 
confirmation of this construct, PCR product of VL-CL was subsequently inserted into pBud-131 
VH-CH at KpnI/XhoI sites to generate pBud-VH-CH-VL-CL (pBud-c-1T0), which contains 132 
the heavy and light-chain sequences of mouse-human chimeric antibody (Figure 1).  133 
PCR1 reactions were performed in 20 μl volume, containing 1 μl of cDNA extracted from VH 134 
and CH or VL and CL, 2 mM MgSo4 concentration, 1u/μl Pfu DNA polymerase (Fermentas) 135 
and 10X reaction buffer. After 3 min denaturation at 94ºC, the PCR reaction was followed by 136 
5 cycles of 1 min at 92ºC, 1 min at 58ºC, 1.5 min at 72ºC. The temperature was hold on 137 
92ºC for 3min and after addition of external primers in 5μl volume containing 10X reaction 138 
buffer, PCR2 reaction was performed by 35 cycles of 1 min at 92ºC, 1 min at 58ºC, 1.5 min 139 
at 72ºC and a final cycle at 72ºC for 10 min. To confirm the identity of PCR products, the 140 
amplified VH-CH and VL-CL genes were cloned into pGEM-T vector (Promega) and 141 
sequenced. 142 
 143 
144 
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Table 1: Sequences of PCR primers 145 
 146 
Primer  Amplified genes Sequence Amplicon size
mUIgVH-S VH CAGGTSMARCTGCAGSAGTCWGG 348 bp 
mUIgGHC-AS VH AGGGGCCAGTGGATAGACAGATGG 
mUIgVκL-S Vκ GAHRTTSWGNTSACYCAGWCTCCA 321 bp 
mIgκC-AS Vκ  TGGTGGGAAGATGGATACAG 
Cκ-S Cκ ACTGTGGCTGCACCATCTGTCTTCATCTTCCC  318 bp 
XhoICκ-AS Cκ (SOE PCR) CTCGAGCTAACACTCTCCCCTGTTGAAGCTCTTTGTGACGGGCGA 
CH-S Cγ1 GCCTCCACCAAGGGCCCATCGGTC  990 bp 
BamHICH-AS Cγ1 (SOE PCR) GGATCCTCATTTACCCGGAGACAGGGAGAGGCTCTT 
Vκ-kpn-T-S VκT0 (SOE PCR) GGTACCGCCACCATGGAGTTTCAGACCCAGGTCTTTGTATTCGTGTT
G 
381 bp 
Jκ-T-AS VκT0 (SOE PCR) AAGCTTTTTTATTTCCAGCTTGGTCCCCCCTCCGAACGTG 
VH-SalI-T-S VHT0 (SOE PCR) GTCGACGCCACCATGGACTTTGGGTTCAGCTTG  405 bp 
JH-T-AS VHT0 (SOE PCR) GCCCTTGGTGGAGGCAAGCTTTGAGGAGACGGTGAG 
(In degenerate primers, R=A or G, S=C or G, K=G or T, M=A or C, Y=C or T, W=A or T, H= A, T 147 
or C, N= A, T, C or G). 148 
 149 
Transfection of chimeric antibody and establishment of stable transfected 150 
cell lines 151 
To develop a stable transfectant expressing chimeric 1T0 antibody (c-1T0), CHO cells were 152 
grown to 80% confluency in 12-well culture plates. pBud-c-1T0 construct was prepared using 153 
Plasmid Maxiprep (Qiagen, Stockholm, Sweden) and then, CHO-K1 cells were transfected with 154 
6 µg DNA of pBud-c-1T0 construct in combination with 6 µL JetPEI transfection reagent 155 
(Polyplus-transfection, New York, NY) according to the manufacturer’s recommendations. After 156 
48 h culture, transient expression of c-1T0 was assessed by ELISA. To establish stable 157 
transfectant, cells were subsequently selected using 1mg/ml of Zeocin (Gibco, Grand Island, 158 
NY, USA) within a minimum of two weeks.  159 
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 160 
Screening of chimeric antibody production by ELISA 161 
Chimeric antibody activity was detected using an indirect ELISA method [12]. In brief, a 96-well 162 
ELISA plate (Maxisorp, Nunc, Roskilde, Denmark) was coated with 0.5 µg/mL recombinant 163 
extracellular part of HER2 (eBioscience Inc., San Diego, USA) in PBS and incubated 1.5 h at 164 
37°C and blocked with PBS supplemented with 0.05% Tween (Sigma, St Louis, MO, USA) and 165 
3% non-fat skim milk. Fifty microliters of supernatants of transfected CHO cells were added at 166 
37°C for 1.5 h. Trastuzumab was used as positive control. After washing with PBS-Tween, 167 
horseradish peroxidase (HRP)-conjugated rabbit anti-human Ig (prepared in our lab) was added 168 
and plate incubated for 1 h at 37°C. After further washing, the reaction was revealed with 169 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate (Sigma). Sulfuric acid was added to stop the 170 
reaction and the optical density (OD) was measured by a multiscan ELISA reader (Organon 171 
Teknika, Turnhout, Belgium) at 450 nm.  172 
 173 
Structural characterization of chimeric antibody by ELISA and SDS-PAGE 174 
Stable transfected cells producing c-1T0 were adapted to serum free medium (EX-CELL™ 175 
Sp2/0, Sigma, St Louis, MO, USA). Supernatant of c-1T0 was purified using a 1 ml HiTrap 176 
Protein G HP column (Amersham Biosciences, New Jersey, USA). The culture supernatant 177 
(1 litre) was passed through the column and the column was subsequently washed 178 
thoroughly with PBS. Bound recombinant chimeric antibody was eluted by 50 ml of elution 179 
buffer (0.1 M glycine/HCl, pH 2.7; flow rate 1 ml/min). The pH of eluted fraction was 180 
immediately normalized using 1 M Tris/HCl, pH 9.0 buffer. For verification of c-1T0, we 181 
examined presence of human IgG1 and IgCκ in c-1T0 antibody by ELISA method. Briefly, a 182 
96-well ELISA plate was coated with 5 µg/mL mouse monoclonal antibody against human 183 
IgG (8a4, kindly provided by Professor Roy Jefferis) in PBS. SPG purified c-1T0 in different 184 
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concentrations were added at 37°C for 1.5 h. Herceptin was used as positive control. After 185 
washing, horseradish peroxidase (HRP)-conjugated rabbit anti-human Ig and sheep anti-186 
human IgCκ was added separately for assessment of human IgG1 and IgCκ and the plate 187 
was incubated for 1 h at 37°C. After further washings, the reaction was revealed with TMB 188 
substrate. Sulfuric acid was added to stop the reaction and ODs were measured as 189 
mentioned above. 190 
The structure of c-1T0 antibody was analysed by SDS-PAGE [14]. Briefly, 500 ng of SPG 191 
purified c-1T0 antibody was separated on 10% SDS-PAGE under reducing and non-192 
reducing conditions and visualized with silver staining. Herceptin was used as a positive 193 
control. After electrophoretic separation, the gel was washed three times with distilled water 194 
and incubated for 30 min with 50 ml of fixing solution (Methanol 50 ml, acetic acid 10 ml and 195 
40 ml H2O). Three times washing was repeated and the gel was incubated 1 min with 50 ml 196 
of 0.2g/lit solution of sodium thiosulphate. After further washings, the gel was incubated 25 197 
min with 50 ml of silver nitrate solution (20%). The gel was subsequently washed and developed 198 
with a solution containing sodium carbonate (30g/lit), 100µl of formaldehyde (37-41%) and 4 ml 199 
sodium thiosulphate (0.2g/lit). Finally, citric acid (3%) was added to stop the reaction. 200 
 201 
Analysis of specific binding of chimeric antibody to rHER2 by Western blot 202 
technique 203 
Western blot was employed to compare specific binding of mouse 1T0 and c-1T0 to rHER2. 204 
Fifty nanogram of rHER2 was separated on 12% SDS-PAGE and transferred to PVDF 205 
membrane (Roche Diagnostics, Mannheim, Germany). After blocking of membrane with 206 
blocking buffer (PBS-Tween-20 containing 5% non-fat skim milk) overnight at 4ºC and washing 207 
three times with washing buffer (PBS-Tween-20) for 15min, mouse 1T0 and c-1T0 antibodies 208 
were added at 10 µg/mL in blocking buffer at room temperature for 1.5 h while shaking. Ten 209 
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µg/mL of Herceptin was used as a positive control. Washing steps were repeated and HRP-210 
conjugated sheep anti-mouse immunoglobulin (prepared in our lab) for mouse 1T0 and HRP-211 
conjugated sheep anti-human Ig (prepared in our lab) for c-1T0 and Herceptin were added at 212 
room temperature for 1.5 h on shaker. After washing, PVDF membrane was treated with ECL 213 
(Amersham Biosciences, New Jersey, USA) and the bands were visualized on Kodak X-ray 214 
film (Eastman Kodak, Rochester, NY, USA). 215 
 216 
Affinity constant determination by ELISA 217 
An ELISA-based method was used to define the binding affinity of mouse 1T0 and c-1T0 [15]. 218 
Briefly, wells of a micotiter ELISA plate were coated with several concentrations (2-0.031 219 
µg/mL) of recombinant extracellular part of HER2. After blocking with  0.05% Tween (Sigma) 220 
and 3% non-fat skim milk, serial concentrations of mouse 1T0 (10-0.15 µg/mL) and c-1T0 (5-221 
0.07 µg/mL) in blocking buffer were added into coated wells and incubated at 37ºC for 1.5 h. 222 
Washing was repeated and wells incubating with HRP-conjugated sheep anti-mouse Ig and 223 
sheep anti-human Ig (prepared in our lab) for 1.5 h at 37ºC. After the final wash step, TMB 224 
substrate solution was added followed by stopping solution and ODs were measured. Sigmoidal 225 
curves of ODs versus the logarithm of antibody concentrations were constructed. The antibody 226 
concentration giving 50% of the maximum absorbance value ([Ab]t) at a particular antigen 227 
coating concentration was chosen for the affinity measurement using the formula Kaff = 1/2(2 228 
[Ab0]t - [Ab]t). [Ab0]t and [Ab]t represent the antibody concentrations resulting in 50% of the 229 
maximum absorbance value at two consecutive concentrations of coated antigen where [Ag] = 230 
2[Ag0]. The mean of such calculations for three non-overlapping antigen concentrations was 231 
taken as the final Kaff value. 232 
 233 
Analysis of cell surface binding of chimeric antibody by flow cytometry 234 
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Indirect staining at surface membrane level was performed on BT-474 cells (National Cell Bank 235 
of Iran, Tehran, Iran). After trypsinization, 106 cells were harvested, washed two time with 236 
washing buffer (PBS, 0.1% NaN3), and incubated with 100 µL of 10 µg/mL of mouse 1T0 and c-237 
1T0 antibodies as primary antibodies at 4ºC for 1 h. Mouse IgG1 mAb and human IgG of 238 
irrelevant specificity (produced in our lab) were included as negative controls. After incubation 239 
and washing process, cells were incubated with FITC-conjugated sheep anti-mouse Ig and 240 
sheep anti-human Ig (prepared in our lab) at 4ºC for 1 h. The cells were finally scanned by a 241 
flow cytometer (Partec, Nuremberg, Germany). Flomax flow cytometry analysis software 242 
(Partec) was used to analyse the data. 243 
 244 
Assessment of tumor growth inhibition by XTT assay 245 
For tumor growth inhibition experiments, BT-474 cells were seeded in 96-well flat-bottom tissue 246 
culture plates (30000 cells/well) in serum-containing RPMI-1640 medium (Gibco, Grand Island, 247 
NY, USA). The cells were treated with different concentrations of mouse 1T0, c-1T0 and 248 
Herceptin (10, 2 and 0.2 µg/ml) for 16h at 37ºC in a humidified atmosphere of 5% CO2. After 249 
incubation, the RPMI medium was exchanged with serum free medium containing XTT solution 250 
(Roche, Indianapolis, IN) for 16h at 37ºC as recommended by the manufacturer. After 251 
incubation with XTT, microtiter plates were read by an ELISA reader (Organon Teknika, 252 
Turnhout, Belgium) at 450 nm with the reference wavelength of 690 nm. Controls included 253 
background (cells only) and Herceptin. All experiments were performed in triplicate. The 254 
following formula was used to estimate the tumor growth inhibition rate induced by anti-HER2 255 
antibodies:  256 
Tumor growth inhibition (%) = [(OD without antibody- OD with antibody)/OD without 257 
antibody]×100 258 
 259 
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Assessment of tumor proliferation inhibition by radioactive thymidine 260 
incorporation assay 261 
 The antiproliferative activity of mouse 1T0 and c-1T0 was tested on HER2-overexpressing cell 262 
line BT-474. BT-474 cells were seeded in 96-well flat-bottom tissue culture plates and were 263 
allowed to recover and adhere overnight. Antibodies were added to wells at different 264 
concentrations of mouse 1T0, c-1T0 and Herceptin (10, 2 and 0.2 µg/ml) for 16h at 37ºC in a 265 
humidified atmosphere of 5% CO2. After incubation, 3H-thymidine (PerkinElmer, Boston, USA) 266 
was added at 0.5 µCi per well for 8 h. Cultures were then harvested and transferred to 267 
scintillation fluid for measurement of 3H-thymidine incorporation by a beta counter (Wallac 1410 268 
Liquid Scintillation Counter, Pharmacia, Sweden). Controls included background (cells only) and 269 
Herceptin. All experiments were performed in triplicate. The following formula was used to 270 
estimate the proliferation inhibition rate:  271 
Proliferation inhibition (%) = [(CPM without antibody-CPM with antibody)/CPM without 272 
antibody]×100  273 
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Results 274 
Amplification of the VH and VL genes of mouse 1T0 mAb 275 
The VH and VL genes were amplified using specific primers designed for the leader 276 
sequences of VH and VL genes (Figure 2, A and B). The ORF of the VH region of the mAb 277 
1T0 is 405 bp in length, encoding a 135-aa polypeptide and the ORF of VL is 381 bp in 278 
length, encoding a 127-aa polypeptide, including the leader peptides. Both VH and VL 279 
genes have a signal leader sequence on their N-terminal region, encoding 19- and 20-aa 280 
polypeptides, respectively. The Cκ and CΥ1 were amplified with specific primers from cDNA 281 
of normal human PBMC encoding 107- and 330-aa polypeptides, respectively (Figure 2, C 282 
and D). Finally, the VLT0-Cκ and VHT0-Cγ1 segments (Figure 2, E and F) were linked to 283 
each other by SOE PCR technique as described in the Materials and Methods.  284 
 285 
Expression of chimeric c-1T0 antibody in CHO cells 286 
The c-1T0 construct was transfected in CHO cells by JetPEI transfection reagent and 287 
culture supernatants were collected to assess chimeric antibody production by antigen 288 
specific indirect ELISA. After selection in Zeocin and four rounds of subcloning, a stable 289 
transfected cell line (c17) that produces high levels of chimeric antibody was selected. 290 
Based on the results obtained from the antigen specific ELISA using recombinant 291 
extracellular region of HER2 as the coating antigen and different concentrations of 292 
Herceptin as the standard protein, 960 ng/ml of chimeric antibody was detected in serum 293 
free medium (Figure 3, A and B).  294 
 295 
Structural characterization of c-1T0 antibody 296 
  15
Transfected CHO cells were maintained in a serum-free culture medium. The chimeric 297 
antibody was purified from the culture supernatant by affinity chromatography using SPG 298 
column. The purified chimeric antibody was analysed by SDS-PAGE under non-reducing 299 
and reducing conditions. Silver staining of SDS-PAGE gel (Figure 4) shows monomeric 300 
(~150 kDa) form of the chimeric antibody under non-reducing condition (c-1T0, lane 1). The 301 
monomeric light  (~25 kDa) and heavy chains (~50 kDa) were detected under reducing 302 
conditions (c-1T0, lane 2). The parental mouse 1T0 mAb gave a similar pattern under non-303 
reducing and reducing conditions. 304 
Western blot analysis revealed that the chimeric c-1T0 and the parental mouse 1T0 mAbs 305 
react with the non-reduced recombinant extracellular HER2 protein (Figure 5). Lack of 306 
reactivity with the reduced HER2 protein indicates recognition of a conformational epitope 307 
by our mAb. A similar pattern of reactivity was observed for Trastuzumab, which was used 308 
as a control.   309 
 310 
Affinity constant determination 311 
The binding affinity of the chimeric antibody was determined by an ELISA method as 312 
described in the Materials and Methods. Based on the binding curves obtained for 313 
the chimeric and mouse parental mAbs (Figure 6, A and B), the mean Kaff of mouse 314 
1T0 and c-1T0 were 0.6×109 and 1.3×109, respectively. 315 
 316 
Assessment of cell binding activity by flow cytometry 317 
In order to determine the binding reactivity of c-1T0 to the HER2 overexpressing 318 
cells, we performed flow cytometric analysis using c-1T0 and mouse 1T0 as first 319 
layer and sheep-anti human-FITC and sheep-anti mouse-FITC as second layer, 320 
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respectively. In parallel to Trastuzumab as positive control, c-1T0 showed positive 321 
reactivity and detected HER2 on surface of BT-474 cells similar to the parental 322 
mouse 1T0 antibody (Figure 7). 323 
 324 
Tumor cell growth inhibition by c-1T0 chimeric mAb  325 
A colorimetric (XTT) assay was performed to assess the effect of c-1T0 on growth of 326 
BT-474 cell line. The growth inhibition rate of triplicate wells was determined and percent 327 
of inhibition was calculated according to the formula described in the Materials and 328 
Methods. Accordingly, c-1T0 induced a dose dependent growth inhibition, similar to the 329 
parental mouse 1T0 mAb in the BT-474 tumor cell line (Figure 8).  330 
 331 
Tumor proliferation inhibition by c-1T0 chimeric mAb 332 
The ability of c-1T0 to inhibit tumor cell proliferation was assessed in vitro in parallel to 333 
the parental mouse 1T0 mAb by radioactive labeled thymidine assay. The stimulation 334 
index of triplicate wells was determined and percent of inhibition of cell proliferation was 335 
calculated for mouse 1T0 and c-1T0 (Figure 9). Both mAbs induced a similar dose 336 
dependent pattern of inhibition.  337 
338 
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Discussion 339 
Monoclonal antibodies are a part of the biological drugs that represent a growing 340 
segment of the pharmaceutical industry. Approximately 26 mAbs have so far been 341 
approved by FDA and over 200 mAbs are still awaiting approval [16]. An early 342 
success of mouse mAb for therapeutic purposes provoked a response similar to 343 
serum sickness of antisera therapy [17]. When a mouse mAb is multiply injected to a 344 
patient, the human anti-mouse antibody response (HAMA) is induced [18]. 345 
Chimerization is one approach to reduce the immunogenicity of therapeutic mouse 346 
mAb for human treatment. In 1984, Boulianne et al. [19] and Morrison et al. [20] 347 
produced chimeric antibodies by joining the mouse variable domains to human 348 
constant domains. Although chimerization reduces HAMA response of murine 349 
antibodies, human anti-chimeric antibody (HACA) response could be created 350 
because of immunogenic epitopes in the mouse variable regions. Despite their 351 
potential immunogenicity, chimeric antibodies have been widely used for 352 
immunotherapy of cancers. One of the most widely used therapeutic chimeric 353 
antibodies is Rituximab. If these antibodies prove to be effective in vivo then their 354 
humanization might be considered later, particularly if they are found to be highly 355 
immunogenic in human. Another approach to further reduce the immunogenicity of 356 
murine mAb is humanization in which all framework regions (FWR) residues that are 357 
not essential for antigen binding are replaced with human FWR counterpart 358 
sequences [21].  359 
  18
HER2 gene overexpression has been found in a number of human malignancies 360 
[22] and is a proven therapeutic target. In 1990, Fendly and coworkers [23] 361 
produced mAbs directed against extracellular domain of HER2. Two of these 362 
antibodies, 4D5 and 2C4 were shown to inhibit growth of breast cancer cells both in 363 
vitro and in vivo [24]. These mouse mAbs were chimerized and subsequently 364 
humanized and designated as Trastuzumab and Pertuzumab [25, 26]. Trastuzumab 365 
is a humanized mAb that binds to the extracellular domain IV of HER2, and induces 366 
down-regulation of the PI3K/Akt pathway. Treatment with Trastuzumab has proven 367 
to be effective in management of HER2-amplified/overexpressing tumors [27]. 368 
Nevertheless, resistance to therapy is a serious challenge [28]. The majority of 369 
metastatic breast cancer patients who initially respond to Trastuzumab begin to 370 
demonstrate disease progression within one year [29]. Newly generated mAbs with 371 
specificity to novel epitopes on extracellular domain of HER2 [9, 12, 30] might be 372 
able to enhance anti-cancer activity. Synergistic effect of some mAbs with 373 
Trastuzumab has been demonstrated in HER2 overexpressing breast cancer 374 
xenograft models [8, 31]. Among these antibodies, FDA has approved Pertuzumab 375 
(Perjeta-Genentech) in combination therapy with Trastuzumab [11]. Pertuzumab is 376 
another humanized mAb that binds to domain II and efficiently inhibits dimerization 377 
of HER2 [32].  378 
We have recently generated a panel of mouse mAb directed against HER2 which 379 
recognize epitopes distinct from Trastuzumab [12]. Two of these mAbs (1T0 and 380 
2A8) were later found to significantly inhibit the proliferation of HER2-expressing 381 
tumor cell line, BT-474, dose-dependently (manuscript in preparation). In the present 382 
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study, we presented data on chimerization of one of these mAbs, 1T0. The VH and 383 
VL genes were successfully amplified and integrated to human IgG1 and Cκ by SOE 384 
PCR. Liu and colleagues [33] generated a mouse/human chimeric mAb against 385 
HER2 and assessed its structural and biological activities. They amplified the VH 386 
and VL genes of the mouse mAb from genomic DNA of the hybridoma clone. Luo 387 
and coworker [34] isolated Fab genes of a mouse mAb from cDNA of hybridoma cell 388 
line and constructed a mouse/human chimeric mAb. Either DNA sequencing or 389 
ELISA could be used to show that the expression vector of chimeric antibody is 390 
constructed successfully [34, 35]. The results of ELISA in this work showed that the 391 
transfected CHO cells produce mouse/human chimeric mAb (c-1T0). 392 
Using an antigen based indirect ELISA as well as immunoblotting techniques we 393 
demonstrated the HER2 binding activity of the chimeric c-1T0 antibody. The 394 
immunoblot results showed that similar to the parental mouse 1T0 mAb, c-1T0 395 
recognizes a conformational epitope on extracellular domain of HER2 (Figure 5). 396 
The results obtained by flow cytometry indicate that c-1T0 binds to native HER2 397 
expressed on the surface of tumor cells as efficiently as the mouse counterpart and 398 
Trastuzumab (Figure 7). These findings suggest that this antibody could be used to 399 
target tumor cells. Interestingly, the affinity constant of the chimeric antibody was 400 
slightly higher than the parental mouse 1T0 mAb. The improved binding activity of 401 
our chimeric antibody might be due to the higher flexibility of the hinge region of 402 
human IgG1 as compared to mouse IgG1. A similar mouse/human chimeric IgG1 403 
mAb with specificity for Cryptococcus neoformans and a higher binding affinity 404 
compared to the parental mouse IgG1 mAb has previously been reported [36]. 405 
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The in vitro biological activity of our chimeric antibody was assessed by 406 
incorporation of radioactive thymidine and XTT techniques (Figure 8 and 9). The 407 
results indicated that c-1T0 inhibits the proliferation of BT-474 cells dose 408 
dependently similar to Trastuzumab and the mouse 1T0. However, despite the 409 
overall similarity, c-1T0 displayed a better inhibitory response in the XTT assay, but 410 
not the thymidine incorporation assay, which could be due to the differences of the 411 
assay systems employed in this study. The XTT assay measures the metabolic 412 
activity of the growing cells, whereas the thymidine incorporation assay measures 413 
the DNA synthesis status of proliferating cells. Furthermore, Trastuzumab failed to 414 
inhibit cell growth and proliferation at low concentration (2.5ug/ml) in both assay 415 
systems, implying functional limitation of this mAb at low concentrations.  416 
The mechanisms of anticancer activity of c-1T0 are not completely known, but taking 417 
into consideration the similar in vitro tumor growth inhibitory activity of c-1T0 and 418 
Trastuzumab, several mechanisms could be proposed including: (a) downregulation 419 
of total levels of HER2 on the cell surface [37], (b) blocking cleavage of the 420 
extracellular domain of HER2 and thereby preventing formation of the constitutively 421 
active membrane-bound 95-kDa HER2 protein called p95HER2 [28], (c) induction of 422 
cell cycle arrest by p27kip1 and inhibition of cdk2 activity [38] and (d) blocking of the 423 
dimerization of HER2 with HER3. 424 
Considering the synergistic anti-tumor effect induced by combination of two different 425 
mAbs with different epitope specificities, such as Trastuzumab and Pertuzumab [8] 426 
and the fact that c-1T0 recognizes an epitope of HER2 different from that recognized 427 
by Trastuzumab, our mAb might display a synergistic anti-tumor effect in 428 
  21
combination with Trastuzumab or Pertuzumab. We are currently investigating the 429 
biological activity of c-1T0 mAb alone and in combination with Trastuzumab antibody 430 
in vivo in nude mice implanted with breast tumor cells to assess its potential 431 
implication for immunotherapy of HER2-expressing malignancies. Further in vivo 432 
investigations are also required to assess functional activities of c-1T0 mAb 433 
mediated by the host T lymphocytes and NK cells, such as antibody-dependent cell 434 
cytotoxicity. 435 
 436 
 437 
Executive Summary 438 
The oncogenic potential and accessibility of HER2 have made it a suitable target for 439 
cancer immunotherapy by monoclonal antibodies. 440 
This study describes chimerization and characterization of a new mouse mAb (1T0) 441 
against HER2, which binds to an epitope of HER2 different from that of 442 
Trastuzumab. 443 
The chimeric antibody was expressed in eukaryotic cells and characterized by 444 
ELISA, SDS-PAGE and flow cytometry. 445 
Tumor cell growth and proliferation inhibition were assessed by XTT and thymidine 446 
incorporation assays, respectively. 447 
c-1T0 recognized a conformational epitope within the extracellular domain of HER2 448 
distinct from Trastuzumab and displayed a binding affinity comparable to the 449 
parental mouse mAb.  450 
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The purified chimeric mAb induced a dose dependent cell growth and proliferation 451 
inhibition similar to the parental mouse mAb in HER2 overexpressing BT-474 tumor 452 
cell line. 453 
Our chimeric mAb with specificity to a novel epitope on extracellular domain of 454 
HER2 is potentially a suitable tool for targeted immunotherapy of HER2 455 
overexpressing malignancies.  456 
457 
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Figure 1: 458 
 459 
Map of pBudCE4.1 expression vector containing the mouse-human chimeric antibody (c-1T0). Light chain 460 
sequences were introduced in XhoI and KpnI sites after PEF-1α promoter and heavy chain sequences were 461 
introduced in SalI and BamHI sites after PCMV promoter. 462 
463 
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Figure 2: 464 
A465 
B466 
C467 
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D468 
E469 
F 470 
PCR amplification of VH-CH and VL-CL genes for construction of the chimeric antibody. Mouse variable region 471 
heavy (VH) and light (VL) chain genes (A and B) and human constant region heavy chain of IgG1 (Cγ1) and 472 
kappa light chains (Cκ) (C and D) were amplified from cDNA of the mouse hybridoma 1T0 clone and cDNA of 473 
human PBMC, respectively. Vκ-Cκ (E) and VH-Cγ1 (F) fragments were amplified by SOE PCR as described in 474 
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Materials and Methods. The PCR products were run in 1% agarose gel. A 100bp Plus DNA ladder (A,C,D and 475 
F) (Sinaclone, Iran) and DNA molecular weight marker IX (B and E) (Roche, Germany) were used. 476 
Figure 3: 477 
A478 
B 479 
Measurement of chimeric anti-HER2 mAb in culture supernatant of transfected cells. Titration of Trastuzumab 480 
(A) and c-1T0 culture supernatant (B) on recombinant extracellular region of HER2 is shown. Supernatant of 481 
Mock transfected CHO cell line was used as a control (dot line).   482 
483 
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Figure 4: 484 
 485 
SDS-PAGE electrophoresis pattern of chimeric antibody. SPG purified c-1T0 and mouse 1T0 IgG 486 
preparations were separated on 10% gel in non-reducing (1 and 3) and reducing (2 and 4) 487 
conditions. MW: molecular weight ladder (Sinaclon, Iran). 488 
489 
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Figure 5: 490 
 491 
Western-blot analysis of chimeric antibody. Non-reduced (NR) and reduced (R) forms of rHER2 extracellular 492 
protein was separated on 10% SDS-PAGE gel and transferred onto nitrocellulose membrane. The membrane 493 
was blotted with c-1T0 (Lanes 3 and 6), mouse 1T0 (Lanes 2 and 5) and Trastuzumab (Lanes 1 and 4) and 494 
then visualized by ECL, as described in Materials and Methods. 495 
496 
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Figure 6: 497 
A B 498 
Experimental dose-response curves for mouse 1T0 (A) and chimeric c-1T0 (B) monoclonal antibodies at three 499 
different concentrations of recombinant extracellular HER2 protein. 500 
 501 
Figure 7: 502 
 503 
Detection of binding activity of chimeric c-1T0 antibody to HER2-expressing BT-474 cells by 504 
flow cytometry. BT-474 were harvested and stained with mouse 1T0 and chimeric c-1T0. 505 
Irrelevant mouse mAb (mIgG), irrelevant human IgG (hIgG) and Trastuzumab were used with 506 
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the same concentration as negative and positive controls, respectively. Figures represent 507 
percent of positive cells. 508 
509 
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Figure 8: 510 
 511 
Assessment of tumor growth inhibition activity of chimeric antibody by XTT assay. Serial 512 
concentrations of c-1T0 antibody were added to BT-474 cells. Cells were then incubated with 513 
XTT and OD was measured. Percent of inhibition was measured as described in Materials and 514 
Methods. Serial concentrations of mouse 1T0 and Trastuzumab were employed as controls. 515 
516 
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Figure 9: 517 
 518 
Assessment of tumor proliferation inhibition activity of chimeric antibody by radioactive 519 
thymindine incorporation assay. Serial concentrations of antibody were added to BT-474 cells. 520 
Cells were then incubated with 3H thymidine and radioactive thymidine incorporation was 521 
subsequently measured by a beta-counter. Percent of proliferation inhibition was calculated as 522 
described in Materials and Methods. 523 
524 
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